Evidence map›Paper›PMID 23610520›Full record

ArticleInternational journal of nanomedicine2013

A nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery system.

Erdal Eroglu, Pooja M Tiwari, Alain B Waffo, Michael E Miller, Komal Vig, Vida A Dennis, Shree R Singh

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Biopolymer-based Carriers for DNA Vaccine Design.Angewandte Chemie (International ed. in English) · 2021
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Erdal ErogluCenter for NanoBiotechnology Research, Alabama State University, Montgomery, AL 36104, USA.
Pooja M Tiwari
Alain B Waffo
Michael E Miller
Komal Vig
Vida A Dennis
Shree R Singh
Alabama State University · USAuburn University · US

Funding

RISE Option II:NIGMS-Research Initiative for Scientific Enhancement (RISE) Program at ASUR25GM106995 · NIGMS · ALABAMA STATE UNIVERSITY · PI DENNIS, VIDA A · 2013 to 2023
$3.0M
NIGMS NIH HHS R25 GM106995
6 · The paper itself

Abstract

The transport of DNA into eukaryotic cells is minimal because of the cell membrane barrier, and this limits the application of DNA vaccines, gene silencing, and gene therapy. Several available transfection reagents and techniques have been used to circumvent this problem. Alternatively, nonviral nanoscale vectors have been shown to bypass the eukaryotic cell membrane. In the present work, we developed a unique nanomaterial, pHEMA+chitosan nanospheres (PCNSs), which consisted of poly(2-hydroxyethyl methacrylate) nanospheres surrounded by a chitosan cationic shell, and we used this for encapsulation of a respiratory syncytial virus (RSV)-F gene construct (a model for a DNA vaccine). The new nanomaterial was capable of transfecting various eukaryotic cell lines without the use of a commercial transfection reagent. Using transmission electron microscopy, (TEM), fluorescence activated cell sorting (FACS), and immunofluorescence, we clearly demonstrated that the positively charged PCNSs were able to bind to the negatively charged cell membrane and were taken up by endocytosis, in Cos-7 cells. Using quantitative polymerase chain reaction (qPCR), we also evaluated the efficiency of transfection achieved with PCNSs and without the use of a liposomal-based transfection mediator, in Cos-7, HEp-2, and Vero cells. To assess the transfection efficiency of the PCNSs in vivo, these novel nanomaterials containing RSV-F gene were injected intramuscularly into BALB/c mice, resulting in high copy number of the transgene. In this study, we report, for the first time, the application of the PCNSs as a nanovehicle for gene delivery in vitro and in vivo.

Indexed as

Analysis of VarianceAnimalsChitosanChlorocebus aethiopsCOS CellsDrug CarriersFemaleGene DosageMiceMice, Inbred BALB CNanospheresPolyhydroxyethyl MethacrylatePolymerase Chain ReactionRespiratory Syncytial VirusesRespiratory Syncytial Virus VaccinesRNA, MessengerChitosanDrug CarriersPolyhydroxyethyl MethacrylateRespiratory Syncytial Virus VaccinesRNA, MessengerVaccines, DNAViral Envelope Proteinsnonviral vectorpHEMA+chitosan nanoparticlesRSV-DNA vaccine

Identifiers

PMID23610520
PMCPMC3629879
OpenAlexW2030907941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.